Hegedus L, Okumus O, Mairinger F, Ploenes T, et al. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Lung Cancer 2023;178:237-246.
PMID: 36907051